patent.fyi
Applications  /  US 2026/0355184
United States Patent Application Publication

US 2026/0355184 A1

Published
Nov 12, 2026
Filed
Sep 27, 2023
Earliest date on the face
Sep 27, 2022
Classification
A61K 31/498
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1A nitrile at R1

What ifWhat if R1 is a directly attached nitrile group?
Claim language“substituted or unsubstituted alkyl”

The scaffold bonds directly to the carbon of the nitrile. The linear carbon–nitrogen triple bond gives the substituent a narrow profile and places a hydrogen bond acceptor at its tip.

1.2Separate groups at adjacent positions

What ifWhat if R2 and R3 are separate fluorine and methyl substituents with no ring joining the two attachment sites?
Claim language“joined together to form a carbocyclic, heterocyclic, aryl, or heteroaryl ring”

A carbon–fluorine bond occupies one attachment site, and a carbon–carbon bond attaches methyl at the other. The fluorine contributes a local bond dipole, while the methyl group adds hydrophobic surface at the neighboring position.

1.3Internal alkyne as linker

What ifWhat if an internal carbon–carbon triple bond links the two attachment points?
Claim language“substituted or unsubstituted alkylene or heteroalkylene”

Each end of the linker bonds directly to one of the two sp-hybridized carbons. The geometry at those carbons aligns the attachment bonds along the triple-bond axis.

1.4Acyclic group at R4

What ifWhat if R4 is a tert-butyl group?
Claim language“substituted or unsubstituted aryl”

The linker attaches to the central carbon of the tert-butyl group. Three methyl branches provide a compact hydrophobic surface with tetrahedral geometry at the attachment carbon.

1.6Ether oxygen at X2

What ifWhat if X2 is an ether oxygen bonded to both neighboring scaffold carbons?
Claim language“or —N(Rc)—”

The oxygen connects the two neighboring carbons through single bonds. The resulting C–O–C segment has a bent geometry and provides a hydrogen bond acceptor.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Surface residue testing in manufacturing

A reference solution of the small molecule serves as a calibration material for testing residues on pharmaceutical equipment. A technician wipes a defined area with a solvent-wetted swab and extracts the swab into a measured volume of solvent. Liquid chromatography measures the compound in the extract, and the result is corrected using recovery measured on a reference surface of the same material.

Component substitution

Cyclodextrin carrier for aqueous samples

Hydroxypropyl beta cyclodextrin replaces a portion of the organic cosolvent in an aqueous analytical preparation of the small molecule. A concentrated solution of the compound is mixed into buffered cyclodextrin solution and brought to the final volume with buffer. The cyclodextrin cavity associates reversibly with hydrophobic portions of the molecule, and liquid chromatography measures the concentration recovered in the clarified liquid.

Parameter or scale variation

Microscale measurement of solution stability

Sealed glass inserts each hold 100 microliters of a 10 micromolar solution of the small molecule in the selected formulation vehicle. Replicate inserts are held at 4 and 25 degrees Celsius and sampled at 0, 24, and 72 hours. Liquid chromatography measures the parent compound at each time point against a freshly prepared calibration series.

Combination with existing systems

Flow through dissolution with chromatographic sampling

A flow-through dissolution cell holds a solid dosage unit containing the small molecule, and a pump delivers temperature-controlled medium through the cell. A downstream filter retains suspended particles, and a fraction collector gathers the effluent at timed intervals. Liquid chromatography measures the dissolved concentration in each fraction, and the measured fraction volumes determine the cumulative mass released.

Humidity cycling with solid form measurements

A humidity chamber exposes separate portions of the powdered small molecule to programmed humidity cycles at a fixed temperature. At the end of each humidity hold, replicate portions are transferred to sealed holders for powder X-ray diffraction and to vials for water-content measurement by coulometric titration. Comparison with the starting material tracks changes in crystalline form and water uptake across the cycle.

Automated or data-driven variant

Automated tracking of reference solution stability

An autosampler stores sealed reference solutions and injects them at scheduled intervals alongside freshly prepared calibration solutions. Software identifies the parent peak using a retention-time window and calculates concentration from the calibration curve. The software associates each result with its vial identifier and elapsed storage time and flags values below a configured concentration threshold.

Specific version of a part

Ether linker with terminal methylenes

L is a methylene–oxygen–methylene segment with one terminal methylene at each attachment point. The central ether oxygen accepts hydrogen bonds, and rotation about the carbon–oxygen bonds lets the segment adopt multiple conformations.

Meta-fluorophenyl group at R4

R4 is a phenyl ring that attaches to L at ring carbon 1 and bears fluorine at ring carbon 3. The ring provides a planar aromatic surface with the carbon–fluorine bond oriented meta to the attachment site.

Imine nitrogen at X1

X1 is nitrogen with one single bond and one double bond to its neighboring scaffold atoms. In the neutral form, the nitrogen lone pair provides a hydrogen bond acceptor.

Cyclopropyl group on nitrogen

Rc is an unsubstituted cyclopropyl group attached to the X2 nitrogen through a ring carbon. The three-membered ring constrains the geometry of the two carbon–carbon bonds at that attachment carbon.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 8,680,136 B2
Published
Mar 25, 2014
Filed
Aug 8, 2011
Class
A61K 31/44
Document BUS 2019/0307776 A1
Published
Oct 10, 2019
Filed
Jun 28, 2017
Class
A61K 31/58
Claim 1
Document A
Document B
1.1R1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl
R1 is selected from a group consisting of —C1-9alkyl, —C2-9alkenyl, —C2-9alkynyl, —NR9R10, —C1-9alkylR11, —C2-9alkenylR11, —C2-9alkynylR11, -carbocyclyl-R11, —CH(OH)C1-9alkylR9, —CH(OH)C2-9alkenylR9, —CH(OH)C2-9alkynylR9, —CH(OH)carbocyclyl-R9, —C(═O)R9, —C(═O)C1-9alkylR9, —C(═O)C2-9alkenylR9, —C(═O)C2-9alkynylR9, —C(═O)C2-9carbocyclyl-R9, —C(═O)NR9R10, —N(R9)C(═O)R9, —N(R9)C(═O)NR9R10, —N(R9)C(═O)OR9, —N(R9)C(═O)C(═NR10)R9, —N(R9)C(═O)C(═CR9R10)R9, —N(R9)C(═O)C1-4alkylN(R9)C
A · US 8,680,136 B2 · ¶ 13
1.2each of R2 and R3 are independently hydrogen, halogen, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or R2 and R3, together with the atoms to which they are attached, are joined together to form a carbocyclic, heterocyclic, aryl, or heteroaryl ring, each of which may be optionally substituted
each R7 is independently selected from a group consisting of H, halo, —C1-9alkyl, —C2-9alkenyl, —C2-9alkynyl, —NR9R10, —OR9, —C1-9alkylCO2R9, —C2-9alkenylCO2R9, —C2-9alkynylCO2R9, and -carbocyclyl-CO2R9, or independently: (i) R6 and an R7 are taken together with the atoms to which they are attached to form a substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl, (ii) R7 and an R8 are taken together with the atoms to which they are attached to f
A · US 8,680,136 B2 · ¶ 18
R8 and R9 are independently selected from —H, —C1-6 alkyl, —C1-6 substituted alkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl, —C1-6 alkyl-Q2, and —COOR3, alternatively R8 and R9 are taken together with the adjacent N to form a cycle selected from: V is selected from —CR24R25—, —SO2—, —O— and —NR12—;
B · US 2019/0307776 A1 · claim 28
1.3L is substituted or unsubstituted alkylene or heteroalkylene
A compound having the structure of formula I: or a pharmaceutically acceptable salt thereof, wherein: Y is a 1-4 atom alkylene, optionally substituted by one or more substituents selected from the group consisting of Cl, F, CN, CF3, —R9, —OR9, —C(═O)NR9R10, and —C(═O)OR9, wherein said alkylene or alkenylene linker is optionally fused to an optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carbocyclyl, or optionally substituted heterocyclyl
A · US 8,680,136 B2 · claim 1
1.4R4 is substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl
R4 is selected from —H, —C1-6 alkyl, —C1-6 alkyl-C(OR3)2—C3-6 cycloalkyl, —C1-6 substituted alkyl, —C1-6 alkyl-C3-6 cycloalkyl, —C1-6 alkyl-Q1, —C1-6 alkyl-C3-6 cycloalkyl-Q1, aryl, heteroaryl, substituted heteroaryl, —COR6, —COCOR6, —SO2R7, and —SO2NR2R2, wherein Q1 is selected from C3-10 carbocycle, substituted C3-10 carbocycle, C3-10 heterocycle, substituted C3-10 heterocycle, aryl, heteroaryl, substituted heteroaryl, halogen, —CF3, —OR2, —COOR2, —NR8R9, —CONR10R11 and —SO
B · US 2019/0307776 A1 · claim 28
1.5X1 is —C(Ra)═ or —N═
“Azaindole” means one of the “CH” moieties in the 6-member ring of an indole is substituted with a nitrogen atom.
B · US 2019/0307776 A1 · ¶ 70
1.6X2 is —C(Rb)2— or —N(Rc)—
1.7Ra is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl
Ra is C1-6 alkyl, NR2R2, Rb is —H, —C1-6 alkyl, —COR3, —SO2R3, —SONR3R3, R5 is selected from —H, —C1-6 alkyl, —C3-6 cycloalkyl, —C1-6 alkylsubstituted alkyl, —C1-6 alkyl-NR8R9, —COR6, —COCOR6, —SO2R7 and —SO2NR2R2; with the proviso that only one of R4 or R5 can be selected from —COR6, —COCOR6, —SO2R7 and —SO2NR2R2;
B · US 2019/0307776 A1 · claim 28
1.8each of Rb is independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl
R12 is selected from a group consisting of H, C1-9alkyl, —(CH2)0-3—R11, —C(R13)2OC(O)C1-9alkyl, —C(R13)2OC(O)R11, —C(R13)2OC.(O)OC1-9alkyl and —C(R13)2OC(O)OR11; each R13 is independently selected from a group consisting of H and C1-4-alkyl; and m is independently an integer from 1 to 2, wherein each C1-9alkyl, C2-9alkenyl, and C2-9alkynyl is independently optionally substituted.
A · US 8,680,136 B2 · claim 1
R24 and R25 are independently from the group of H, —C1-6 alkyl, —C1-6 substituted alkyl, —C1-6 alkyl-Q5, —C1-6 cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl, and Q5 is selected from halogen and SO2R3, R26 and R27 are independently selected from —H, —C1-6 alkyl, —C1-6 substituted alkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl, —C1-6 alkyl-Q2, and
B · US 2019/0307776 A1 · ¶
1.9Rc is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
R10 and R11 are independently selected from —H, —C1-6 alkyl, —C1-6 substituted alkyl and —C3-6 cycloalkyl, alternatively R10 and R11 are taken together with the adjacent N to form a cycle such as R12 is selected from —C1-6 alkyl, —C1-6 alkyl-OH; —C1-6 alkyl, —C1-6 substituted alkyl,-C3-6 cycloalkyl, —COR7, —COONR22R23, —SORT, and —SONR24R25;
B · US 2019/0307776 A1 · claim 28

An empty cell means only that no passage was reproduced there.

Statements in these documents
The present invention relates to antimicrobial compounds, compositions, their use and preparation as therapeutic agents.
A · US 8,680,136 B2 · ¶ 2
The rapid spread of bacterial resistance and the evolution of multi-resistant strains severely limits β-lactam treatment options available.
A · US 8,680,136 B2 · ¶ 4
Despite the armamentarium of agents and drug combinations, there remains a medical need for new anti-retroviral agents, due in part to the need for chronic dosing to combat infection.
B · US 2019/0307776 A1 · ¶ 4
The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions, and their use in inhibiting HIV and treating those infected with HIV or AIDS.
B · US 2019/0307776 A1 · ¶ 7
Cite aspatent.fyi, US 2026/0355184 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355184/, SHA-256 8855a309bf557d2fc9e65ea1bf418ab52ff93347bbf27385a4f789a68882cdd7
First published
Permanent addresshttps://patent.fyi/US20260355184/
Content fingerprint (SHA-256)8855a309bf557d2fc9e65ea1bf418ab52ff93347bbf27385a4f789a68882cdd7
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi